The FDA has issued an order for General Snus on October 22, 2019, which authorizes us to make the following statement:
Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
The FDA and other public health authorities agree that when it comes to tobacco and nicotine products, there is a continuum of risk. The continuum acknowledges that lighting tobacco on fire and inhaling the resultant smoke causes the most harm.
This places *combustible* cigarettes at the highest risk levels of the continuum, while Swedish snus and other non-combustible tobacco and nicotine products (like nicotine pouches, e-cigarettes, and smokeless tobacco) inhabit the lower risk levels of the continuum.
A Modified Risk Tobacco Product (MRTP) is defined as a product that reduces harm or the risk of tobacco-related disease and will benefit the health of the population as a whole. On October 22, 2019 the FDA issued an order for General Snus which authorizes us to make the following statement:
Using General Snus instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung canger, stroke, emphysema, and chronic bronchitis.
As of October 2019, the FDA has issued a single Modified Risk Tobacco Products order for General Snus.
General Snus has a long history of harm reduction outside of the United States with its relative risk closely examined and well-documented. This is extremely apparent in Sweden and Norway. In Sweden, widespread use of snus in place of cigarettes has been tied to helping the country achieve the lowest lung and oral cancer rates in men in Europe, despite tobacco use rates being similar to other countries. In Norway, we saw snus rates among young women increase to 13 percent since it was introduced in 2002. In the almost exact same time span, smoking rates among young women dropped from 30 percent to one percent. For more information, click here.